bioRxiv · 17 Nov 2026
Elucidating the Sodium Channel-Targeting Anti-Seizure Medication Interactome: A Drug-Target Pathway Analysis
Srinivasan Ekambaramh-index 14, Erika T. Axeen, Jaideep Kapur, Howard P Goodkin, Nikolay V. Dokholyanh-index 77
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Epilepsy is a common neurological disorder in both children and adults, primarily managed with anti-seizure medications (ASMs). Sodium channel blockers are among the most commonly used ASMs. These medications exhibit distinct spectra of efficacy and side effect profiles. These likely result from different off-target interactions, protein binding profiles, and subunit selectivity that remain poorly characterized. We developed a neural network-based computational pipeline to systematically elucidate the molecular targets and associated biological pathways of selected sodium channel-modulating ASMs: carbamazepine, lamotrigine, eslicarbazepine, licarbazepine, lacosamide, phenytoin, and cenobamate. Using the DRIFT (Drug-target identification based on chemical similarity) algorithm for proteome-wide target prediction, we identified protein targets for these ASMs. The sodium channel alpha subunit family was the highest-ranked target for every drug except cenobamate, for which it ranked second behind the GABA-A receptor. Pathway mapping in the Reactome database revealed both shared and drug-specific biological processes. Furthermore, molecular docking studies elucidated the atomistic interactions between the drugs and the predicted targets. Specifically, the predicted target landscape varied from eslicarbazepine and licarbazepine (59 predicted targets each) to lacosamide (18). Pathway analysis revealed recurrent enrichment in rapid depolarisation and the interaction between L1 and ankyrins shared across all drugs, alongside predicted off-targets, including the cannabinoid CB1 receptor for phenytoin and the carbonic anhydrases for lacosamide. Molecular docking supported these predictions, with binding scores ranging from -24 to -31 kcal/mol. Overall, this work provides a systems-level view of NaV-targeting ASM pharmacology and a hypothesis-generating framework to prioritize mechanistic and combination studies of these medications in epilepsy.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Nikolay V. Dokholyan has the highest h-index among the authors (77).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.